MedPath

Rivastigmine

Generic Name
Rivastigmine
Brand Names
Exelon, Nimvastid, Prometax, Rivastigmine Sandoz, Rivastigmine 1 A Pharma, Rivastigmine Hexal, Rivastigmine Actavis
Drug Type
Small Molecule
Chemical Formula
C14H22N2O2
CAS Number
123441-03-2
Unique Ingredient Identifier
PKI06M3IW0
Background

Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase.

Indication

For the treatment of mild to moderate dementia associated with Parkinson's disease or of the Alzheimer's type.

Associated Conditions
Dementia With Lewy Body Disease, Mild Dementia due to Parkinson's disease, Mild Dementia of the Alzheimer's Type, Moderate Alzheimer's Type Dementia, Moderate Dementia due to Parkinson's disease
Clinical Trials
Related News

Effect of Heat on Rivastigmine TDS Products

Early Phase 1
Completed
Conditions
Bioavailability
Interventions
First Posted Date
2019-04-16
Last Posted Date
2022-04-04
Lead Sponsor
University of Maryland, Baltimore
Target Recruit Count
7
Registration Number
NCT03915626
Locations
🇺🇸

General Clinical Research Center (GCRC) at the University of Maryland Medical Center, Baltimore, Maryland, United States

Cholinergic Neurotransmission in Mobility and Cognition in Parkinson Disease

Phase 4
Completed
Conditions
Parkinson Disease
Parkinson Disease Dementia
Interventions
First Posted Date
2019-02-15
Last Posted Date
2023-12-20
Lead Sponsor
University of Maryland, Baltimore
Target Recruit Count
31
Registration Number
NCT03840837
Locations
🇺🇸

University of Maryland School of Medicine, Dept. of Neurology, Baltimore, Maryland, United States

Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (9.5mg/24h)

Phase 1
Completed
Conditions
Bioequivalence
Interventions
Drug: RID-TDS 9.5 mg/24 h
First Posted Date
2018-09-06
Last Posted Date
2019-09-19
Lead Sponsor
SocraTec R&D GmbH
Target Recruit Count
58
Registration Number
NCT03659435
Locations
🇩🇪

SocraTec R&D GmbH, Clinical Pharmacology Unit, Erfurt, Thüringen, Germany

Rivastigmine BA Trial With Multiple Application of Transdermal Patches, Adaptation and Tapering Phase

Phase 1
Completed
Conditions
Bioequivalence
Interventions
Drug: RIV-TDS 13.3 mg/24 h
First Posted Date
2018-06-29
Last Posted Date
2018-08-21
Lead Sponsor
SocraTec R&D GmbH
Target Recruit Count
36
Registration Number
NCT03573050
Locations
🇩🇪

SocraTec R&D GmbH, Clinical Pharmacology Unit, Erfurt, Thüringen, Germany

A Phase IV Study to Evaluate Safety, Tolerability and Effectiveness of Rivastigmine Patch 15cm2 in Patients With Severe Dementia of the Alzheimer's Type.

Phase 4
Completed
Conditions
Alzheimer's Disease
Interventions
First Posted Date
2016-12-12
Last Posted Date
2024-05-31
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
100
Registration Number
NCT02989402
Locations
🇮🇳

Novartis Investigative Site, Kolkata, West Bengal, India

Efficacy of RIVAstigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear Palsy

Phase 3
Completed
Conditions
Progressive Supranuclear Palsy (PSP)
Interventions
Drug: Placebo
First Posted Date
2016-07-21
Last Posted Date
2023-07-20
Lead Sponsor
Assistance Publique Hopitaux De Marseille
Target Recruit Count
106
Registration Number
NCT02839642
Locations
🇫🇷

Service de Neurologie et Pathologie du Mouvement Hôpital de La Timone, Marseille Cedex 5, France

NextStep:Study to Evaluate Safety,Efficacy & Tolerability of Rivastigmine Patch in Mild to Moderate Alzheimer's Patients.

Phase 4
Completed
Conditions
Mild to Moderate Alzheimer's Disease
Interventions
First Posted Date
2016-03-09
Last Posted Date
2019-09-12
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
118
Registration Number
NCT02703636
Locations
🇯🇵

Novartis Investigative Site, Okayama, Japan

Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage AD Having Coexisting svCVD

Phase 4
Completed
Conditions
Alzheimer Disease
CVA (Cerebrovascular Accident)
Interventions
First Posted Date
2015-05-14
Last Posted Date
2021-03-05
Lead Sponsor
National Neuroscience Institute
Target Recruit Count
100
Registration Number
NCT02444637
Locations
🇸🇬

National Neuroscience Institute, Singapore, Singapore

Rivastigmine Patch Effect on the Post-operative Delirium in Patients at Risk of Dementia.

Phase 4
Completed
Conditions
Delirium
Interventions
First Posted Date
2015-04-10
Last Posted Date
2015-04-10
Lead Sponsor
Chung-Ang University Hosptial, Chung-Ang University College of Medicine
Target Recruit Count
62
Registration Number
NCT02413554

Pharmacovigilance in Gerontopsychiatric Patients

Phase 3
Terminated
Conditions
Dementia
Depression
Schizophrenia
Psychosomatic Disorders
Anxiety Disorders
Interventions
First Posted Date
2015-03-02
Last Posted Date
2018-02-28
Lead Sponsor
Hannover Medical School
Target Recruit Count
407
Registration Number
NCT02374567
Locations
🇩🇪

Bezirkskrankenhaus Augsburg, Augsburg, Germany

🇩🇪

Krankenhaus Hedwigshöhe, Berlin, Germany

🇩🇪

Hannover Medical School, Hannover, Germany

and more 2 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy